Evidence map›Paper›PMID 41325130›Full record

ArticleHepatology communications2025

Development of an AI algorithm for early identification of MASLD in the electronic health record.

Ariana Stuart, Ashley Dotson, Katya Swarts, Marion Granich, Jessica Yeung, Arthi Thirumalai, Manish Dhyani, James Perkins, Rotonya Carr

Abstract read
In one paragraph

Article in Hepatology communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ariana StuartDepartment of Medicine, University of Washington, Seattle, Washington, USA.
Ashley DotsonDepartment of Medicine, University of Washington, Seattle, Washington, USA.
Katya SwartsDivision of Gastroenterology, University of Washington, Seattle, Washington, USA.
Marion GranichQuality and Population Health Analytics, University of Washington, Seattle, Washington, USA.
Jessica YeungQuality and Population Health Analytics, University of Washington, Seattle, Washington, USA.
Arthi ThirumalaiDivision of Metabolism, Endocrinology and Nutrition, University of Washington, Seattle, Washington, USA.ORCID 0000-0003-1239-2614
Manish DhyaniDepartment of Radiology, University of Washington, Seattle, Washington, USA.
James PerkinsDivision of Transplant Surgery, University of Washington, Seattle, Washington, USA.ORCID 0000-0002-6935-0012
Rotonya CarrDivision of Gastroenterology, University of Washington, Seattle, Washington, USA.ORCID 0000-0003-0235-6994

Funding

Molecular Mechanisms Of Post-Transplant Recurrent Alcoholic Liver DiseaseR01AA026302 · NIAAA · UNIVERSITY OF WASHINGTON · PI ROTONYA M CARR · 2017 to 2026
$3.2M
NIAAA NIH HHS R01 AA026302
6 · The paper itself

Abstract

backgroundMetabolic dysfunction-associated steatotic liver disease (MASLD) affects ~30% of the US adult population, and its prevalence is increasing. Early-stage disease is often missed by clinicians as it is largely asymptomatic until cirrhosis develops. Recent advances in artificial intelligence (AI) have allowed for expanded electronic health record (EHR) identification of several diseases. We aimed to develop an algorithm that utilizes AI to identify patients with MASLD via a large-scale review within the EHR.

methodsWe created a natural language processing (NLP) algorithm that identifies patients with hepatic steatosis on abdominal imaging and selects for patients meeting MASLD criteria. Validation was carried out via manual review of monthly generated cohorts. The algorithm was then utilized to retrieve a MASLD cohort for initial analysis. Demographics were summarized, and additional variables pertaining to early MASLD management were analyzed.

resultsOur algorithm identified patients with MASLD with a positive predictive value (PPV) of over 93%. The NLP component of the algorithm identified hepatic steatosis in imaging reports with a PPV of up to 99.4% and excluded patients with alcohol use with a negative predictive value of ~95%. From a cohort spanning 6 months, 957 individuals with MASLD were identified by the algorithm, of which 14.6% (n=140) had a MASLD-related diagnosis code.

conclusionsWe developed an AI algorithm that can perform a large-scale review of electronic health records to identify patients with MASLD with >93% accuracy. Our initial analysis suggests that a substantial proportion of individuals meeting MASLD criteria do not yet carry a MASLD-related diagnosis. Our work can be adapted by other institutions to enhance the detection of MASLD and alcohol use patterns, allowing for targeted interventions to prevent disease progression and improve outcomes.

Indexed as

AlgorithmsArtificial IntelligenceElectronic Health RecordsFatty LiverAdultAgedEarly DiagnosisFemaleHumansMaleMiddle AgedNatural Language ProcessingPredictive Value of Testsdiagnosisiterative refinementliver diseasemachine learningnatural language processing

Identifiers

PMID41325130
PMCPMC12668588

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.